Kabazitaksel Fresenius Kabi

Cabazitaxel, the active ingredient in Kabazitaksel Fresenius Kabi, is a taxane presented as an injectable solution for intravenous use. It is indicated for metastatic castration‑resistant prostate cancer after prior docetaxel therapy.

GNH USA supplies Kabazitaksel Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Kabazitaksel is a taxane chemotherapy used in the treatment pathway of advanced prostate cancer.

Metastatic castration‑resistant prostate cancer: provides a therapeutic option after docetaxel failure, improving disease control and overall survival.

Cabazitaxel is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Anemia: lowered red blood cells causing weakness. - Nausea and vomiting: gastrointestinal upset. - Diarrhea: loose stools that may lead to dehydration. - Alopecia: hair loss on scalp and body.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Life‑threatening infections: sepsis or opportunistic infections. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Peripheral neuropathy: numbness or tingling in extremities. - Cardiac events: arrhythmias or myocardial ischemia.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for toxicity.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: evaluate hepatic enzymes as cabazitaxel is hepatically cleared. Evaluate for hypersensitivity: observe for infusion‑related reactions during administration. Avoid in severe infection: postpone dosing until infection resolves. Use with caution in the elderly: consider dose adjustments based on tolerance. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cabazitaxel may interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise cabazitaxel plasma levels. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Concurrent myelosuppressive agents: increase risk of severe neutropenia.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may modestly increase exposure. - Anticoagulants (e.g., warfarin): heightened bleeding risk due to platelet effects. - CYP2C8 substrates (e.g., paclitaxel): potential additive toxicity.